Viewing Study NCT06586294



Ignite Creation Date: 2024-10-26 @ 3:39 PM
Last Modification Date: 2024-10-26 @ 3:39 PM
Study NCT ID: NCT06586294
Status: NOT_YET_RECRUITING
Last Update Posted: None
First Post: 2024-09-04

Brief Title: A Study of Anti-PD-1 and LAG-3 Bispecific AntibodyAK129 Combined With Chemotherapy With or Without Cadonilimab in the First-line Treatment of Unresectable Locally Advanced or Metastatic G GEJ Adenocarcinoma
Sponsor: None
Organization: None

Study Overview

Official Title: A Phase IbII Open LabelDose Escalation and Dose Extension Study Evaluating the Safety Tolerability and Initial Antitumor Efficacy of Anti-PD-1 and Lymphocyte Activation Gene 3LAG-3 Bispecific Antibody AK129 Combined With Chemotherapy With or Without Cadonilimab in Patients With Human Epidermal Growth Factor Receptor 2 HER2 Negative Unresectable Locally Advanced or Metastatic GGEJ Adenocarcinoma
Status: NOT_YET_RECRUITING
Status Verified Date: 2024-09
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: No
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: Phase IbII clinical study of AK129 combined with chemotherapy with or without cadonilimab in first-line treatment of advanced HER2 negative gastric cancer or gastroesophageal junction adenocarcinoma
Detailed Description: None

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None